IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

Table 2

Correlations of IL-17 expression with clinical characteristics in patients with LC.

Clinical characteristics			IL-17 expression
Gender				0.280
	Male	35
	Female	25
Age				0.321
	<50	22
	≥50	38
TNM stage	I/II	27		0.007
	III/IV	33
Degree of differentiation				0.009
	Middle/high	42
	Low	18
LNM				<0.0001
	Yes	38
	No	22
Tumor site				0.285
	Glottis	26
	Supraglottis	20
	Subglottis	4
T classification	Tis	8		0.013
	T1/T2	23
	T3/T4	29

LC: laryngeal cancer; TNM: tumor node metastasis; LNM: lymph node metastasis.